STAT3 is a key element in many oncogenic pathways and, like other transcription factors, is an attractive target for development of novel anticancer drugs. However, interfering with STAT3 functions has been a difficult task and very few small molecule inhibitors have made their way to the clinic. Recently, OPB-31121, a compound currently in clinical trials, has been reported to affect STAT3 signaling although its mechanism of action has not been unequivocally demonstrated. In this study we used computational experimental approaches to define the molecular target and the mode of interaction of OPB-31121 with STAT3. To validate our approach, similar studies were performed with known STAT3 inhibitors (STAT3i). Docking and molecular dynamics simulation (MDS) showed that OPB-31121 interacted with a distinct pocket in the SH2 domain of STAT3.
INTRODUCTION
Signal Transducers and Activators of Transcription (STATs) are a family of latent cytoplasmic proteins that once activated regulate many aspects of cell growth, survival and differentiation (Levy and Darnell, 2002; Yu et al., 2009) . STAT proteins act as signal transducers and transcription factors with the ability to transmit signals from the cell membrane to the nucleus without the involvement of second messengers (Levy and Darnell, 2002; Yu et al., 2009 ). The STAT family includes seven members (STAT1, 2, 3, 4, 5a, 5b, and 6) that share extensive structural homology . The main structural motifs of STAT proteins are the N-terminal domain (NTD), coiled-coil domain (CCD), DNA-binding domain (DBD), Src Homology 2 domain (SH2) and C-terminal domain (CTD). The NTD and CCD are required for nuclear translocation and protein-protein interaction, respectively (Levy and Darnell, 2002; Lim and Cao, 2006) . The DBD is necessary for the recognition of specific DNA sequence elements and binding to gene promoters. The SH2 domain is the most conserved domain of the family and is required for formation of STAT3 dimers (Lim and Cao, 2006) . Phosphorylation of a specific tyrosine residue in the CTD of STAT proteins allows the interaction of the SH2 domains of monomers and formation of active dimers (Lim and Cao, 2006; Zhong et al., 1994) . In the case of STAT3, phosphorylation of tyrosine 705 (pY705) is the key event to promote dimerization.
Binding of cytokines and growth factors to the respective receptors and consequent activation of the receptor-associated tyrosine kinases, like Janus Kinases (JAK), induce pY705 ).
This event is critical to promote dimerization and nuclear translocation of STAT3 and activation of STAT3 transcriptional functions ). Non-receptor-associated kinases, such as Src, also catalyze Y705 phosphorylation and activate STAT3 signaling. In addition to Y705, STAT3 is phosphorylated at serine 727 (pS727) by serine protein kinases (Zhang et al., 1995) . pS727 has been described to enhance the transcriptional activity of STAT3 (Wen et al., 1995) . However, 4 recently pS727 has been reported to control mitochondrial localization of STAT3 and mitochondrial functions (Gough et al., 2009; Wegrzyn et al., 2009 ). Other post-translational modifications, like acetylation and methylation, are relevant for STAT3 functions in normal and pathological conditions (Kim et al., 2013a; Lee et al., 2012; Yuan et al., 2005) .
Alterations in the STAT3 signaling pathway are associated with different human diseases (O'Shea and Plenge, 2012) . STAT3 is over-expressed and activated in many human cancers and promotes cell proliferation, survival, tumor angiogenesis and immune-evasion (Sansone and Bromberg, 2012; Yu et al., 2009 ). Activation of the JAK/STAT3 signaling pathway has been shown to contribute to tumor initiation and progression in various cancer models (Yu et al., 2014; Yu et al., 2009) . Recently, activation of STAT3 has been associated with promotion and maintenance of cancer stem-like cell (CSC) properties, tumorigenicity and metastatic capability in many human cancers, including prostate cancer (Kroon et al., 2013; Marotta et al., 2011; Schroeder et al., 2014; Yu et al., 2014) . Consistently, in many cancers activation of STAT3 is associated with advanced, metastatic disease and clinical progression (Sansone and Bromberg, 2012; Yu et al., 2009 ). The JAK/STAT3 pathway contributes also to reduced response to treatment promoting survival and development of resistance after treatment with various kinase inhibitors or androgen deprivation therapy Schroeder et al., 2014; Sos et al., 2014) . We have shown recently that activation of the JAK/STAT3 pathway contributes the establishment of immune-tolerance and chemoresistance in a prostate cancer mouse model through the secretion of immunosuppressive cytokines in the tumor microenvironment (Toso et al., 2014) .
Over-activity of STAT3 in human cancers is frequently the result of deregulation of upstream pathways leading to activation of cytokine and growth factor receptor associated tyrosine kinases, like JAK family kinases (Grivennikov and Karin, 2008; Sansone and Bromberg, 2012; Yu et al., 2014) . However, alternative pathways of STAT3 activation exist (Yu et al., 2014) . Unphosphorylated and S727 phosphorylated STAT3 control transcriptional and non-transcriptional functions of STAT3 (Meier and Larner, 2014; Timofeeva et al., 2012) .
Interestingly, in prostate cancer STAT3 has been reported to induce cell transformation and tumor development in the absence of pY705 (Qin et al., 2008) . The oncogenic effect of STAT3 in this system depended on pS727 and transcriptional dependent and independent functions of STAT3 (Qin et al., 2008) . Acetylation and methylation are also crucial for the role of STAT3 in the acquisition of cancer stem cell-like phenotype and tumorigenic progression (Kim et al., 2013a; Su et al., 2011) .
Because of its central role in multiple oncogenic pathways, STAT3 is an attractive target for development of anticancer drugs and great effort has been devoted over the last decade to the discovery of selective inhibitors (Debnath et al., 2012; Yu et al., 2009 ). Inhibitors of STAT3 are classified as direct and indirect inhibitors (Benekli et al., 2009; Debnath et al., 2012) . Indirect inhibitors are those that interfere with cytokine and growth factor receptors or the associated kinases that activate STAT3 by phosphorylation. Conversely, direct inhibitors interact with the STAT3 protein. Direct STAT3i are expected to block multiple STAT3 functions, like dimerization, nuclear translocation and DNA binding (Debnath et al., 2012) . Direct inhibitors can be further divided according to their target domain, e.g. the NTD, DBD or SH2 domain. Due to its critical involvement in STAT3 activation, the SH2 domain is the most attractive target for STAT3i (Debnath et al., 2012) . Indeed, SH2-targeting compounds constitute the largest class of direct
STAT3i.
Many studies have demonstrated that genetic knockout, knockdown and small molecule inhibitors of STAT3 prevent tumor development and growth in preclinical models (Chan et al., 2004; Kortylewski et al., 2005) . However, despite the preclinical evidence that STAT3 would be an ideal target for cancer therapy, effective strategies to inhibit STAT3 in the clinic are still lacking. This is 6 largely due to the intrinsic difficulty of targeting directly a transcription factor like STAT3 and the diversity of the upstream activating pathways. Consequently, few direct STAT3i have shown relevant activity in preclinical models in vivo and have been tested in clinical trials (Debnath et al., 2012) . OPB-31121 has been recently reported to interfere with STAT3 signaling, although the underlying mechanism has not been clarified yet (Hayakawa et al., 2013; Kim et al., 2013b) .
OPB-31121 exhibits potent anticancer activity in vitro and in tumor xenografts (Hayakawa et al., 2013; Kim et al., 2013b) and is currently investigated in a number of clinical trials (https://clinicaltrials.gov). Understanding how OPB-31121 interacts with STAT3 and the basis of its potent anticancer effect would be highly relevant for further development of this and other STAT3i. In this study, we combined in silico and in vitro experiments to investigate how OPB-31121 and other small molecule inhibitors interact with STAT3 and the functional consequences of these drug-target interactions. Importantly, our study reveals a unique mode of interaction of OPB-31121 with the STAT3 SH2 domain not shared by any of the other STAT3i tested. These unique features might be at the basis of the compound efficacy and make OPB-31121 an interesting lead for further clinical development and design of new direct STAT3i.
MATERIALS AND METHODS

Computational studies
The crystal structures of STAT3 protein was obtained from the available pdb file 1BG1in the Protein Data Bank repository (Becker et al., 1998) . All compounds structures were designed and optimized using Discovery Studio (DS, v. 2.5, Accelrys Inc., San Diego, CA, USA) (Laurini et al., 2011) . All docking experiments were performed with Autodock 4.3 (Morris et al., 2009) , with Autodock Tools 1.4.6 on a win64 platform following a consolidated procedure (Giliberti et al., 2010) . The binding free energy, ∆G bind , between each drug and the protein was estimated resorting 7 to the MM/PBSA (Molecular Mechanics/Poisson-Boltzmann Surface Area) approach. According to this well-validated methodology (Laurini et al., 2012) , the binding free energy was obtained as the sum of the interaction energy between the receptor and the ligand (∆E MM ), the solvation free energy (∆G sol ), and the conformational entropy contribution (−T∆S), averaged over a series of snapshots from the corresponding MDS trajectories. The free energy of binding ∆G bind and the concentration of ligand that inhibits the protein activity by 50% (i.e., IC 50 ) are related by the following fundamental equation: ∆G bind = -RT ln 1/IC 50 , where R is the gas constant and T is the temperature. Thus, once ∆G bind for a given protein/inhibitor couple is estimated by MM-PBSA simulations, the relative IC 50 value is also known by virtue of this relationship. The role of the key residues identified by PRBFED was further studied by performing computational alanine scanning (CAS) experiments (Guo et al., 2012) . Accordingly, the absolute binding free energy of each mutant protein, in which one of the key residue was replaced with alanine, was calculated with the MM/PBSA method and corresponded to the difference in the binding free energy between the wild-type (wt) and its alanine mutant (mut) counterpart.
Cell lines, plasmids, chemicals and antibodies
Human prostate cancer DU-145 and LNCaP cell lines were purchased from American Type Culture Collection and maintained in RPMI supplemented with 10% (FBS) (PAA, Brunschwig, Basel, CH). STAT3 SH2 domain (amino acid residues 586-685) was subcloned into pGEX-2T vector (GE Healthcare Europe GmbH) from pET28a-STAT3-SH2 domain (GenScript USA Inc) using BamHI and EcoRI restriction sites. Mutant constructs were generated using GENEART® Site-Directed Mutagenesis System (Life Technologies). OPB-31121 (Otsuka Pharmaceutical, Tokyo, Japan), STA-21, and Stattic (ENZO LIFE SCIENCES AG, Lausen, CH), S31.201 and Cryptotanshinone (Merck KGaA, VWR, Dietikon, CH) were dissolved in DMSO. IL-6 (10 ng/ml, 8 R&D Systems Europe Ltd., Abingdon, UK), ampicillin (50 µg/ml, Eurobio) and IPTG (isopropyl-β-D-thiogalactopyranoside, 1 mM, Promega, Dübendorf, CH) were dissolved in sterile water. Antibodies against STAT3, pSTAT3 Tyr705, pSTAT3 Ser727, were purchased from Cell Signaling Technology (BIOCONCEPT, Allschwil, CH), and GAPDH from Millipore (Zug, CH).
Western blotting
Cells were washed once in PBS and lysed in lysis buffer (25 mM Tris-HCl pH=7.4, 50 mM KCl, 5 mM EDTA, 1% NP-40, 0.5% Sodium deoxycholate, 0.1% SDS) supplemented with protease and phophatase inhibitors cocktail (Roche Diagnostics (Schweiz) AG, Rotkreuz, CH), sodium orthovanadate (Na 3 VO 4 , Acros Organics) and phenylmethanesulfonylfluoride (PMSF, Sigma-Aldrich). After 20 min of incubation on ice samples were centrifuged for 15 min at 4°C and proteins were quantified using BCA Protein Assay Kit (Pierce, Perbio Science Switzerland SA, Lausanne, CH). Proteins were loaded 10-12% Sprint Next Gel (Amresco, Bioconcept, Allschwil CH) and analyzed by immunoblotting. Membranes were blocked for 1 h with 0.2% of I-Block (Life Technologies) and then probed overnight at 4°C with primary antibodies and for 1 h with horseradish peroxidase (HRP)-conjugated secondary antibodies. Western Bright ECL detection system (WITEC AG, Littau, CH) was used for detection.
Cell viability
DU145 and LNCaP cells were plated in 96-well plates in phenol red-free RPMI supplemented with 10% serum. After 24 h cells were treated with the indicated STAT3 inhibitors. Cell viability was determined using MTT assay after 72 h (Genini et al., 2012) . All assays were performed in triplicate and repeated in at least three independent experiments.
Colony forming assay
Cells were plated in triplicate in 6-well plates. Drugs were added to the medium at increasing concentrations. After 10 days cells were fixed and stained with 1% crystal violet in 20% ethanol.
Colonies were counted with an automated colony counter Alphaimager 3400 (Napoli et al., 2009) .
Results are represented as mean ± SD from 3 independent experiments.
Expression and purification of GST-STAT3 SH2 domain
Escherichia coli strain BL21(DE3) (Life Technologies) transformed with the pGEX-2T-GST-STAT3_SH2 domain plasmids (WT, S636A, and V637A mutants) or pGEX-2T-GST (100 ng of DNA) was grown at 37°C in LB medium containingampicillin (50 µg/ml) to an OD 600 of 0.6-0.7. Cells were then induced with 1 mM IPTG for 4 h at 37°C and subsequently harvested by centrifugation at 4000xg. The bacterial pellet was resuspended in cold PBS containing protease inhibitors plus 1 mg/ml of lysozyme (Sigma-Aldrich) and sonicated (30 seconds of pulsing/30 seconds of pause for 6 times). Triton X-100 (Sigma-Aldrich) was then added at afinal concentration of 1% and the lysate was centrifuged for 20 minutes at 4°C. Supernatant was filtered (0.45 µm), diluted 1:1 with cold PBS and purified by affinity chromatography using GSTrap HP column (GE Healthcare). Fusion proteins were eluted with 10 mM of glutathione, reduced, desalted in PBS and concentrated to 1 mg/ml.
Isothermal titration calorimetry
Isothermal titration calorimetry (ITC) experiments of STAT3i binding to the STAT3 SH2 domain were conducted with a Nano ITC Technology (TA Instruments) at 25°C. After temperature equilibration, GST-SH2 wt, GST-SH2S636A or GS-SH2V637A mutant protein solutions (10 µM) 
Circular dichroism
CD spectra from GSH-SH2 domain WT, GST-SH2S636A or GST-SH2V637A mutants (0.1 mg ml −1 in 10 mM NaPO4, pH 7.4) were recorded on a Chirascan spectropolarimeter (Applied Photophysics) over the wavelength range from 195 to 260 nm at a band width of 1 nm, step size of 0.5 nm and 1s per step. The spectra in the far-ultraviolet region required an average of five scans and were subtracted from blank spectra performed with GST in buffer.
RESULTS
In silico analysis of the binding of OPB-31121 to STAT3
We used various computational approaches to examine in silico the binding of OPB-31121 (Hayakawa et al., 2013; Kim et al., 2013b) to STAT3 (Fig. 1A) . For comparison in our analyses we considered other selected STAT3i, like STA-21 (Song et al., 2005) , Stattic (Schust et al., 2006) , S3I.201 (Siddiquee et al., 2007) and Cryptotanshinone (Shin et al., 2009) , for which there was 11 some previous evidence of binding to the STAT3 SH2 domain. OPB-31121 was docked onto the SH2 domain and then the relevant drug/protein affinities were scored by molecular dynamics simulation (MDS) (Fig. 1B) . The same approach was used for the other compounds (Fig. S1) . Tables 1 and S1 show the values of the calculated IC 50 , free energy of binding ∆G bind and the enthalpic and entropic components predicted for the interaction of each compound with the SH2 domain obtained from the in silico analyses. The calculated IC 50 value for OPB-31121 was in the low nanomolar range (IC 50 ,∼18 nM). Notably, this value was about 2-3 orders of magnitude lower than the IC 50 estimated for the other STAT3i, which ranged from 1.4 to 27.2 µM.
To understand the basis of the remarkable high affinity of OPB-31121 for STAT3 we performed a per-residue deconvolution analysis of the free energy of binding (Fig. 1C) . The resulting interaction spectrum showed that the residues mostly involved in OPB-31121 binding clustered in two regions. Region 1 included residues from Q635 to E638 and region 2 included residues from T714 to T717. Other four residues (i.e., W623, K626, I659, and V667) were found to be engaged in major stabilizing interactions with OPB-31121. The same procedure was applied to the other STAT3i leading to the definition of the STAT3 interaction spectra for each of these compounds ( Fig. S1E-H) . Interestingly, the interaction spectra were compound-specific with very little, if any, overlap between them. The interaction region defined for OPB-31121 was clearly distinct from those of the other STAT3i. A visual representation of these results is given in Fig. 1D , where each drug/STAT3 interaction surface is represented in a different color. Thus, our in silico data indicated that OPB-31121 bound with remarkably high affinity to the STAT3 SH2 domain and that the binding occurred in a distinct pocket and with different residue specificity compared to other STAT3i.
In vitro assessment of the binding of OPB-31121 to the STAT3 SH2 domain
The binding of OPB-31121 to the SH2 domain of STAT3 was investigated in vitro using isothermal titration calorimetry (ITC). Consistent with in silico data, ITC demonstrated high affinity binding of OPB-31121 to recombinant GST-tagged STAT3 SH2 domain yielding an experimental K d of 10 nM ( Fig. 2A) . For comparison we assessed binding of the other STAT3i using ITC in the same experimental conditions. S3I.201 bound to the SH2 domain with substantially lower affinity compared to OPB-31121 (K d = 8 µM) (Fig. 2B) . All other STAT3i
showed similarly low affinity binding with experimental K d in the micromolar range (Fig. S2) .
Notably, these data were in good agreement with the estimated IC 50 values determined by MDS (Table 1) . ITC binding experiments were conducted also with GST protein alone to rule out non-specific binding. None of tested compounds showed any interaction with GST (Fig. S3) .
Hence, the in vitro binding assays supported the computational chemistry prediction of high affinity binding of OPB-31121 to the STAT3 SH2 domain.
In addition to higher binding affinity, the in silico analyses predicted also substantially distinct 
OPB-31121 binding site
To further validate the predicted binding site for OPB-31121 in the STAT3 SH2 domain, we selected two residues (S636 and V637) in the drug-target interaction region defined by binding energy deconvolution analysis. The role of these two residues was first tested in silico by alanine scanning mutagenesis (Fig. 3A-B) . Turning either the S636 or V637 residue into alanine affected the positioning of OPB-31121 in the binding pocket and greatly reduced the binding affinity resulting in a dramatic increase in the estimated IC 50 values to 5 µM and 1.1 µM for S636A and V637A, respectively ( Table 2 ). As proof of the specificity, we applied the same approach to S3I.201. Consistent with the predicted difference in the site of interaction, neither the S636A nor V637A mutation affected significantly the binding mode and the estimated binding affinity of Table 2 ).
S3I.201 (Fig. 3C-D and
In parallel with the in silico studies, we performed in vitro site-directed mutagenesis for the same residues on the GST-tagged STAT3 SH2 domain and assessed binding by ITC. Correct folding of the mutated SH2 domain was determined by comparing circular dichroism (CD) spectra of the wild-type and mutant protein (Fig. S4 ). Both wild type and mutant SH2 domains displayed the typical SH2 spectra indicating that the mutations did not affect the native conformation of the protein. The S636A and V637A mutations abrogated binding of OPB-31121 in ITC experiments, sustaining the validity of the computational model ( Fig. 3E-F) . Interestingly, the binding of the reference compound S3I.201 to the STAT3 SH2 domain was not affected by either mutation,
showing binding affinities similar to that for the wild-type domain ( Fig. 3G-H) .
Inhibition of Y705 and S727 STAT3 phosphorylation by OPB-31121
Next, we assessed the ability of OPB-31121 to interfere with STAT3 phosphorylation at the Y705 and S727 residues in cancer cells. Direct STAT3i would be expected to inhibit the binding of multiple kinases to STAT3 and likely prevent phosphorylation of both Y705 and S727. In these assays, we used two prostate cancer cell lines that exhibited constitutive (DU145) and IL-6 inducible (LNCaP) Y705 phosphorylation, respectively. Cells were treated with increasing concentrations of OPB-31121 for 16 h. IL-6 was added to LNCaP cells during the last 30 min of the incubation to induce pY705. OPB-31121 at concentrations ≥ 5 nM strongly inhibited pY705 in both cell lines ( Fig. 4A-B) . We next determined the kinetics of pY705 inhibition using a dose of 10 nM of OPB-31121. Significant reduction of STAT3 pY705 was achieved within 4-8 h of incubation in both cell lines ( Fig.4C-D) . We assessed in parallel the effect of OPB-31121 on pS727, which in both DU145 and LNCaP cells is constitutively phosphorylated. Interestingly, OPB-31121 reduced pS727 with dose dependence and kinetics similar to those observed for pY705 inhibition in both cell lines (Fig. 4A-D) .
We performed similar experiments with the other STAT3i. All the compounds inhibited pY705 (Fig. 5A) . However, even for the most potent of these compounds (cryptotanshinone) doses ≥ 5 µM were needed to significantly affect pY705. S3I.201, STA-21 and Stattic were active at doses ≥ 20 µM to inhibit pY705 to a comparable level. Notably, these differences in potency reflected closely the differences in the binding affinity between OPB-31121 and the other STAT3i. Interestingly, when we examined the kinetics of inhibition of pY705 and pS727 by cryptotanshinone and S3I.201 a reduction of pY705 was seen within 4 h ( Fig. S5A-B) . However, significant inhibition of pS727 required longer incubation time (8-16 h). Collectively, these experiments showed that OPB-31121, like other STAT3i, reduced both pY705 and pS727. OPB-31121 acted at low doses and within few hours of incubation on both pY705 and pS727. Furthermore, the activity of OPB-31121 was not 15 influenced by the preexisting phosphorylation status of STAT3 and similar effects were seen in cells with constitutive and inducible phosphorylation at Y705. Notably, in these cellular assays OPB-31121 was about 100 to 1000 fold more potent than the other STAT3i tested here, in line with the high in vitro binding affinity of this compound for STAT3.
Antiproliferative activity of OPB-31121 in prostate cancer cells
OPB-31121 has been recently reported to have anticancer activity in various preclinical cancer models (Hayakawa et al., 2013; Kim et al., 2013b) . However, the drug has never been tested in prostate cancer cells. STAT3 activation and increased Y705 and S727 phosphorylation are frequent in human prostate cancer both at the early (androgen-dependent) and late (castration-resistant) stages of the disease and are generally associated with poor clinical outcome (Culig et al., 2005; Dhir et al., 2002; Mora et al., 2002) . Thus, in prostate cancer the availability of compounds that could effectively block pY705 and pS727 and STAT3 signaling through the corresponding downstream pathways could be highly advantageous. Hence, we assessed the effects of OPB-31121 on proliferation of LNCaP and DU145 cells, which are common models of androgen-dependent and castration-resistant prostate cancer, respectively. OPB-31121 inhibited LNCaP and DU145 cell proliferation very effectively with IC 50 values in nanomolar range (18 and 25 nM) (Fig. 6A) . Colony formation was also strongly inhibited by OPB-31121 at doses of 10-50 nM (Fig. 6B ). For comparison we tested the effects of the other STAT3i in both cell lines. All the compounds affected cell proliferation, but the doses required to achieve significant effects were significantly higher than those of OPB-31121 (Fig. 6A ). Higher doses of these STAT3i were also required in the clonogenic assays (Fig. 6B) . Thus, in line with the higher binding affinity, OPB-31121 was substantially more potent in suppressing cell proliferation and colony formation compared to other STAT3i.
DISCUSSION
STAT3 is a latent cytoplasmic transcription factor whose activity is controlled by various post-translational modifications (Yu et al., 2014; Yu et al., 2009 ). Phosphorylation at Y705
enhance nuclear localization and transcriptional activity of STAT3, while pS727 has been reported to control localization and activity of STAT3 in mitochondria (Levy and Darnell, 2002; Yu et al., 2014; Yu et al., 2009 ). STAT3 has an important role in human cancers sustaining neoplastic transformation and promoting tumor progression . Therefore, there is high interest in developing STAT3i for cancer therapy (Debnath et al., 2012) . OPB-31121 has been recently reported to inhibit STAT3 signaling and has relevant anticancer activity in preclinical models in vitro and in vivo (Hayakawa et al., 2013; Kim et al., 2013b) . Based on its activity in preclinical models clinical trials have been initiated with OPB-31121 and are currently ongoing (Hayakawa et al., 2013; Kim et al., 2013b) . Despite its proven efficacy of OPB-31121 in preclinical models, questions remain about its intracellular target and mechanism of action. In this study, we combined computational and experimental approaches to define the mode of interaction of OPB-31121 with STAT3. For comparison, we performed similar studies with a series of structurally distinct STAT3i. To our knowledge, a detailed study of how different small molecules interact with the SH2 domain of STAT3 and how their binding mode impact on the biological activity of the compounds is missing. Indeed, even slight differences in the interaction site and binding affinity might be highly relevant in terms of biological activity and potency of the compounds.
Interestingly, we found that OPB-31121 has a remarkably high affinity for STAT3 and unique mode of interaction with the SH2 domain compared to other STAT3i.
We used computational docking and MDS to examine the potential binding site of OPB-31121 in the SH2 domain of STAT3. The residues in the SH2 domain lining the putative site of binding were identified and those affording the major stabilizing contribution to the binding were investigated by free energy deconvolution and in silico alanine scanning mutagenesis. The same computational procedures were applied to the other STAT3i with the purpose of a direct comparison of the binding modes and sites of interaction. Importantly, these computational predictions were validated by in vitro binding assays using ITC and recombinant STAT3 SH2 domain. Both series of experiments concurred to show that OPB-31121 binds to STAT3 in the SH2 domain with very low Kd. Indeed, both the computationally and experimentally estimated K d values for OPB-31121
were 2-3 orders of magnitude lower than those of the other STAT3i tested in this study. Notably, a similar ranking of the compounds was obtained in the cell-based assays based on their efficacy on STAT3 phosphorylation and cell proliferation. All the data confirmed the substantially higher potency of OPB-31121 compared to the other STAT3i.
In greater details, our in silico analysis identified two distinct binding pockets for small molecule inhibitors in the SH2 domain of STAT3: the first is occupied by OPB-31121 and the second pocket is common to all other inhibitors tested (Fig.1D) . The crystal structure of the STAT3-SH2 domain revealed the existence of one hydrophilic and two hydrophobic sub-pockets (Becker et al., 1998) .
Most STAT3i are predicted to bind either to the hydrophilic site, lined by the side chains of the K591, R609, S611, and S613 residues, or to a partially hydrophobic region composed by the K592, R595, I597, and I634 residues (Fletcher et al., 2008) . Our computational analyses confirmed that all four STAT3i considered here (i.e., cryptotanshinone, STA-21, Stattic, and S3I-201) fit in these two sub-pockets ( Fig. 1D and Fig. S1 ). In contrast, OPB-31121 was found to bind to a distinct region that included the third, hydrophobic sub-pocket (Fig. 1B-C) . OPB-31121 interacted also with a consistently larger number of residues in the SH2 domain compared to the other compounds;
this in turn contributed to the higher affinity of OPB-31121 for STAT3, as indicated by the extremely favorable comparison of estimated IC 50 (Table 1) and K d values ( Fig. 2A) .
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The ITC experiments concurred to support the in silico model of the interaction of OPB-31121 and the other STAT3i with the STAT3 SH2 domain. Competition experiments and site-directed mutagenesis showed the specificity of the interaction site of OPB-31121 in the SH2 domain ( Fig.   2-3) . The presence of a distinct sub-pocket and the high binding affinity of OPB-31121 explain in part the high efficacy of the compound in inhibiting STAT3 phosphorylation in cells. Furthermore, in the case of OPB-31121 inhibition of pY705 and pS727 occurred at similar doses and within the same time scale (∼4h) (Fig. 4) . This was not the case with other STAT3i, like cryptotanshinone and S3I.201, for which the inhibition of pS727 was delayed with respect to pY705 inhibition (Fig. S5) .
Thus, occupying a wider and distinct area in the SH2 domain, OPB-31121 could impair more effectively the interaction of STAT3 with kinases and other proteins and prevent simultaneously and with higher efficiency phosphorylation of these critical residues than other STAT3i.
Collectively, our results demonstrate that OPB-31121 binds to the SH2 domain and interferes directly with STAT3 activation and signaling. Higher binding affinity is likely to lead to higher potency in cellular assays and in vivo, although the compound's propensity to be internalized in cells and metabolized could influence its efficacy in biological systems.
Interfering with JAK/STAT3 signaling has been proposed as a valid option for treatment of prostate cancer (Hedvat et al., 2009; Kroon et al., 2013; Schroeder et al., 2014) . However, blocking pY705 alone may not be sufficient. pS727 is frequently increased in human prostate tumors and has been shown to be sufficient to drive prostate tumorigenesis and progression even independently of pY705 (Qin et al., 2008) . Furthermore, in preclinical models of prostate cancer inactivation of pS727 is sufficient to substantially reduce tumorigenicity (Qin et al., 2008) . In line with the prominent activation of STAT3 signaling in prostate cancer (Culig et al., 2005; Dhir et al., 2002; Mora et al., 2002) , we tested the activity of OPB-31121 in two prostate cancer cell lines, LNCaP and DU145, representative of androgen-dependent and castration-resistant tumors, respectively. We found that OPB-31121 was a potent inhibitor of proliferation and clonogenicity in both cell models (Fig. 6) . Interestingly, the antiproliferative effect of OPB-31121 was independent of the pY705 status and apparently related to the ability of the compounds to block effectively and concomitantly both pY705 and pS727. This raises the possibility that the efficacy of OPB-31121
may not depend exclusively on Y705 activation status and that additional factors should be taken in consideration. Together, these findings suggest also that the use of direct STAT3i like OPB-31121 might be expanded to tumors that do not harbor constitutive pY705 and additional biomarkers (e.g., total and pS727 STAT3 protein level) should be considered to identify potentially sensitive tumor types. 
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